lidocaine and adrenalin

PreclinicalSmall molecule

lidocaine and adrenalin is one of 23 small molecule programs targeting Cardiac Arrhythmia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrhythmiaActive, not recruiting

Cardiac ArrhythmiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Cardiac Arrhythmia

#DrugCompanyPhaseTrials

Colcrys

Alnylam Pharmaceuticals

Klor-Con

Multaq

Tambocor

3 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 6

Epsom Salt

FFresenius Kabi Oncology Ltd.

Approved

1 7

Cordarone

WWyeth-Lederle Vaccines

Approved

1 8

Pronestyl

Bristol-Myers Squibb

Approved

2 9

Quinidine Gluconate

WWyeth-Lederle Vaccines

Approved

—10

Ancef

BBaxter Healthcare Corporation

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiac Arrhythmia1 trial

Evaluation of Cardiac Arrhythmias in Hand Surgery Using Local Anesthesia With Adrenaline

Completed·UUri farkash·N/A·NCT04029610·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for lidocaine and adrenalin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — lidocaine and adrenalin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for lidocaine and adrenalin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Uri farkash company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUri farkash

lidocaine and adrenalin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiac Arrhythmia1 trial

References

Drug Info

Quick Facts

Related News